Bruton's tyrosine kinase inhibitor - Bristol-Myers Squibb

Drug Profile

Bruton's tyrosine kinase inhibitor - Bristol-Myers Squibb

Alternative Names: Btk inhibitor - BMS; BTK-Max

Latest Information Update: 01 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Purines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Immunological disorders

Most Recent Events

  • 02 Mar 2011 Preclinical development in Immunological disorders is ongoing in US
  • 30 Jan 2007 Preclinical trials in Psoriasis in USA (unspecified route)
  • 30 Jan 2007 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top